CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
1.040
+0.030 (2.97%)
At close: Jun 6, 2025, 4:00 PM
1.050
+0.010 (0.95%)
After-hours: Jun 6, 2025, 7:47 PM EDT

CNS Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Selling, General & Admin
5.595.614.775.974.684.39
Upgrade
Research & Development
10.19.2914.19.39.815.06
Upgrade
Operating Expenses
15.6914.918.8715.2714.499.45
Upgrade
Operating Income
-15.69-14.9-18.87-15.27-14.49-9.45
Upgrade
Interest Expense
-0.02-0.02-0.01-0.01-0.01-0
Upgrade
Interest & Investment Income
0.10.060.03---
Upgrade
EBT Excluding Unusual Items
-15.61-14.86-18.85-15.27-14.5-9.46
Upgrade
Pretax Income
-15.61-14.86-18.85-15.27-14.5-9.46
Upgrade
Net Income
-15.61-14.86-18.85-15.27-14.5-9.46
Upgrade
Net Income to Common
-15.61-14.86-18.85-15.27-14.5-9.46
Upgrade
Shares Outstanding (Basic)
10----
Upgrade
Shares Outstanding (Diluted)
10----
Upgrade
EPS (Basic)
-14.69-38.87----
Upgrade
EPS (Diluted)
-14.69-38.87----
Upgrade
Free Cash Flow
-17.17-17.12-14.14-10.56-13.54-7.34
Upgrade
Free Cash Flow Per Share
-16.15-44.78----
Upgrade
EBITDA
-15.69-14.9-18.86-15.26-14.47-9.44
Upgrade
D&A For EBITDA
0000.010.010.01
Upgrade
EBIT
-15.69-14.9-18.87-15.27-14.49-9.45
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q